147 related articles for article (PubMed ID: 36093532)
1. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.
Kim EH; Lee WS; Oh HK
Transl Cancer Res; 2022 Aug; 11(8):2553-2561. PubMed ID: 36093532
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.
Kim JY; Jo Y; Oh HK; Kim EH
Am J Cancer Res; 2020; 10(10):3475-3486. PubMed ID: 33163284
[TBL] [Abstract][Full Text] [Related]
3. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy.
Lee YJ; Cho JM; Sai S; Oh JY; Park JA; Oh SJ; Park M; Kwon J; Shin US; Beak JH; Lim SH; Song JY; Hwang SG; Kim EH
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842288
[TBL] [Abstract][Full Text] [Related]
5. Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer
Jang Y; Lee WS; Sai S; Kim JY; Kim JK; Kim EH
Oncol Lett; 2022 Oct; 24(4):338. PubMed ID: 36039063
[TBL] [Abstract][Full Text] [Related]
6. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma
Davidi S; Jacobovitch S; Shteingauz A; Martinez-Conde A; Braten O; Tempel-Brami C; Zeevi E; Frechtel-Gerzi R; Ene H; Dor-On E; Voloshin T; Tzchori I; Haber A; Giladi M; Kinzel A; Weinberg U; Palti Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740624
[TBL] [Abstract][Full Text] [Related]
7. Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Gkika E; Grosu AL; Macarulla Mercade T; Cubillo Gracián A; Brunner TB; Schultheiß M; Pazgan-Simon M; Seufferlein T; Touchefeu Y
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326718
[TBL] [Abstract][Full Text] [Related]
8. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
9. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
10. [Corrigendum] LYPD8 regulates the proliferation and migration of colorectal cancer cells through inhibiting the secretion of IL‑6 and TNF‑α.
Xu J; Qian J; Zhang W; Chen E; Zhang G; Cao G; Wang F; Shen X; Zhou W; Song Z
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33882644
[TBL] [Abstract][Full Text] [Related]
11. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
12. A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
Al-Khayal K; Vaali-Mohammed MA; Elwatidy M; Bin Traiki T; Al-Obeed O; Azam M; Khan Z; Abdulla M; Ahmad R
BMC Cancer; 2020 Jul; 20(1):685. PubMed ID: 32703189
[TBL] [Abstract][Full Text] [Related]
13. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
14. Hwang-Heuk-San induces apoptosis in HCT116 human colorectal cancer cells through the ROS-mediated activation of caspases and the inactivation of the PI3K/Akt signaling pathway.
Lee MH; Hong SH; Park C; Kim GY; Leem SH; Choi SH; Keum YS; Hyun JW; Kwon TK; Hong SH; Choi YH
Oncol Rep; 2016 Jul; 36(1):205-14. PubMed ID: 27221553
[TBL] [Abstract][Full Text] [Related]
15. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.
Lee WS; Seo SJ; Chung HK; Park JW; Kim JK; Kim EH
Am J Cancer Res; 2021; 11(9):4582-4594. PubMed ID: 34659907
[TBL] [Abstract][Full Text] [Related]
16. Quinalizarin Induces Apoptosis through Reactive Oxygen Species (ROS)-Mediated Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathways in Colorectal Cancer Cells.
Meng LQ; Wang Y; Luo YH; Piao XJ; Liu C; Wang Y; Zhang Y; Wang JR; Wang H; Xu WT; Liu Y; Wu YQ; Sun HN; Han YH; Jin MH; Shen GN; Fang NZ; Jin CH
Med Sci Monit; 2018 Jun; 24():3710-3719. PubMed ID: 29860266
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
18. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines.
Lee WS; Jang Y; Cho A; Kim YB; Bu YH; Yang S; Kim EH
Exp Ther Med; 2023 Aug; 26(2):363. PubMed ID: 37408858
[TBL] [Abstract][Full Text] [Related]
20. Novel quinazoline-based sulfonamide derivative (3D) induces apoptosis in colorectal cancer by inhibiting JAK2-STAT3 pathway.
Al-Obeed O; Vaali-Mohammed MA; Eldehna WM; Al-Khayal K; Mahmood A; Abdel-Aziz HA; Zubaidi A; Alafeefy A; Abdulla M; Ahmad R
Onco Targets Ther; 2018; 11():3313-3322. PubMed ID: 29892198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
